Antibody Test

SARS-CoV-2 Blocking Antibody Test
The Valenta Labs and Viravaxx, in cooperation with a National Diagnostic Center of excellence, recently developed, assembled and cross-validated a proprietary SARS-CoV-2 blocking antibody test. The test is set to become the gold standard as reference test for assessing the correlate of protection, protective immunity, and the efficacy of vaccine candidates crucial to control the COVID-19 pandemic.

Our simple and robust SARS-CoV-2 blocking antibody test mimicks SARS-CoV-2 binding to the ACE2 receptor. It gives an answer about the presence or absence of SARS-CoV-2 or vaccine-induced blocking antibodies.

The test, also referred to as SARS-CoV-2 Neutralization Antibody Detection Test, or SARS-CoV-2 Surrogate Virus Neutralization Test (sVNT), is protected by Viravaxx’ worldwide patent application. It comes in a 96 well ELISA format with ACE2 linked to the plate and appropriately labeled RBD used for detection.